Variability of serum CA 125 levels in healthy women as a function of age, hormonal status, and other conditions

被引:2
作者
Barcelo, B. [1 ]
Barcelo, A. [1 ]
Riesco, M. [1 ]
Perez, G. [1 ]
Castanyer, B. [1 ]
Vila, M. [1 ]
机构
[1] Hosp Univ Son Dureta, Serv Anal Clin, Palma de Mallorca, Spain
来源
CLINICA E INVESTIGACION EN GINECOLOGIA Y OBSTETRICIA | 2006年 / 33卷 / 04期
基金
美国国家卫生研究院;
关键词
D O I
10.1016/S0210-573X(06)74100-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Knowledge of the factors influencing serum concentrations of CA 125 have led the validity of a single cut-off value to be questioned. The aims of the present study were to evaluate CA 125 levels according to age, menopause, body mass index (BMI), smoking, parity, variability during the menstrual cycle, biological variation, index of individuality (II), and critical difference (CD). Sixty-five healthy women distributed in 2 groups, non-menopausal and menopausal, were included. The main results of the study demonstrate that there is a clear relationship between CA 125 levels and age: serum levels of CA 125 were significantly lower in menopausal women than in non-menopausal women, with 95th percentiles of 30.52 U/ml and 18.30 U/ml, respectively. No variations were found during the menstrual cycle, although a CA 125 value higher than the conventional cut-off value was observed during the follicular phase. In non-menopausal women, intra-and interindividual biological variations were 14.23% and 43.57%, while in menopausal women interindividual biological variation was 36.25%. CD was 42.73% and II was 0.11. No significant differences were found between smokers and nonsmokers or according to parity. No relationship was found between CA 125 levels and BMI. In conclusion, knowledge of the factors influencing serum concentrations of CA 125 according to different physiologic and clinical factors and careful adjustment of cut-off values could improve interpretation and identification of subgroups at risk for ovarian carcinoma.
引用
收藏
页码:122 / 129
页数:8
相关论文
共 35 条
[1]   WHAT IS A NORMAL CA125 LEVEL [J].
ALAGOZ, T ;
BULLER, RE ;
BERMAN, M ;
ANDERSON, B ;
MANETTA, A ;
DISAIA, P .
GYNECOLOGIC ONCOLOGY, 1994, 53 (01) :93-97
[2]   A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].
BAST, RC ;
KLUG, TL ;
STJOHN, E ;
JENISON, E ;
NILOFF, JM ;
LAZARUS, H ;
BERKOWITZ, RS ;
LEAVITT, T ;
GRIFFITHS, CT ;
PARKER, L ;
ZURAWSKI, VR ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887
[3]   REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA [J].
BAST, RC ;
FEENEY, M ;
LAZARUS, H ;
NADLER, LM ;
COLVIN, RB ;
KNAPP, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1331-1337
[4]   Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values [J].
Bon, GG ;
Kenemans, P ;
Verstraeten, R ;
vanKamp, GJ ;
Hilgers, J .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 174 (01) :107-114
[5]   Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles [J].
Bon, GG ;
Kenemans, P ;
Dekker, JJ ;
Hompes, PG ;
Verstraeten, RA ;
van Kamp, GJ ;
Schoemaker, J .
HUMAN REPRODUCTION, 1999, 14 (02) :566-570
[6]  
Bonfrer JMG, 1997, CLIN CHEM, V43, P491
[7]  
BROWNING MCK, 1990, J NUCL MED ALLIED S, V34, P89
[8]   Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults [J].
Calle, EE ;
Rodriguez, C ;
Walker-Thurmond, K ;
Thun, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (17) :1625-1638
[9]   Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays [J].
Davelaar, EM ;
Schutter, EMJ ;
von Mensdorff-Pouilly, S ;
van Kamp, GJ ;
Verstraeten, RA ;
Kenemans, P .
ANNALS OF CLINICAL BIOCHEMISTRY, 2003, 40 :663-673
[10]  
Davelaar EM, 1998, CLIN CHEM, V44, P1417